Oncology innovation is progressing rapidly, but pharmaceutical manufacturers face growing challenges, including escalating cost pressures, intense competition, and increasingly crowded disease areas that make product differentiation difficult. Traditional commercialization approaches are becoming less effective as the industry navigates a more complex and fast-moving environment. With the volume and pace of scientific data expanding dramatically, organizations must adopt greater strategic agility to remain competitive and maximize commercial success. As the margin for error continues to shrink, the ability to quickly analyze information, adapt strategies, and make informed decisions has become a critical capability. This installment of EVERSANA’s oncology commercialization series explores

Join for free to read